Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27500892 | 1.00 | USP2 (0.41) | USP2SLCO1B1LMNAL3MBTL1KDM4E | |
| SCHEMBL9235255 | 0.85 | LMNA (0.44) | USP2SLCO1B1LMNAL3MBTL1KDM4E | |
| SCHEMBL468798 | 0.83 | PDE4A (0.50) | USP2SLCO1B1LMNAL3MBTL1KDM4E | |
| SCHEMBL11225324 | 0.83 | PDE4A (0.50) | USP2SLCO1B1LMNAL3MBTL1KDM4E | |
| SCHEMBL468790 | 0.83 | PDE4A (0.50) | USP2SLCO1B1LMNAL3MBTL1KDM4E | |
| SCHEMBL468705 | 0.83 | PDE4A (0.50) | USP2SLCO1B1LMNAL3MBTL1KDM4E | |
| SCHEMBL27182003 | 0.83 | PDE4A (0.50) | USP2SLCO1B1LMNAL3MBTL1KDM4E | |
| SCHEMBL8077206 | 0.81 | LMNA (0.41) | USP2SLCO1B1LMNAL3MBTL1KDM4E | |
| SCHEMBL8072512 | 0.81 | LMNA (0.41) | USP2SLCO1B1LMNAL3MBTL1KDM4E | |
| Acetic Acid SCHEMBL5160517 | 0.81 | PDE4A (0.48) | USP2SLCO1B1LMNAL3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230157971-A1 | COMPOSITIONS AND METHODS FOR NANOPOLYMER-BASED NUCLEIC ACID DELIVERY | MARINE POLYMER TECHNOLOGIES, INC. (US) | 2023-05-25 | — | — | US | claimed |
| EP-2635261-B1 | COMPOSITIONS AND METHODS FOR NANOPOLYMER-BASED NUCLEIC ACID DELIVERY | MARINE POLYMER TECH INC (US) | 2019-10-23 | — | — | EP | claimed |
| US-20170128382-A1 | COMPOSITIONS AND METHODS FOR NANOPOLYMER-BASED NUCLEIC ACID DELIVERY | MARINE POLYMER TECHNOLOGIES, INC. (US) | 2017-05-11 | — | — | US | claimed |
| US-20130287853-A1 | COMPOSITIONS AND METHODS FOR NANOPOLYMER-BASED NUCLEIC ACID DELIVERY | MARINE POLYMER TECHNOLOGIES, INC. (US) | 2013-10-31 | — | — | US | claimed |
| EP-2635261-A2 | COMPOSITIONS AND METHODS FOR NANOPOLYMER-BASED NUCLEIC ACID DELIVERY | MARINE POLYMER TECHNOLOGIES, INC. (US) | 2013-09-11 | — | — | EP | claimed |
| WO-2012061803-A2 | COMPOSITIONS AND METHODS FOR NANOPOLYMER-BASED NUCLEIC ACID DELIVERY | MARINE POLYMER TECHNOLOGIES, INC. (US) | 2012-05-10 | — | — | WO | claimed |
| US-20230157971-A1 | COMPOSITIONS AND METHODS FOR NANOPOLYMER-BASED NUCLEIC ACID DELIVERY | MARINE POLYMER TECHNOLOGIES, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-11534483-B2 | Compositions for the treatment and prevention of hoof and claw diseases | POLYAKOV IGOR (DE) | 2022-12-27 | — | — | US | disclosed |
| US-11173193-B2 | Immunobiological products | POLYAKOV IGOR (DE) | 2021-11-16 | — | — | US | disclosed |
| EP-3429616-B1 | COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF HOOF AND CLAW DISEASES | POLYAKOV IGOR (DE) | 2021-08-04 | — | — | EP | disclosed |
| EP-3429600-B1 | NEW IMMUNOBIOLOGICAL PRODUCTS | POLYAKOV IGOR (DE) | 2021-03-03 | — | — | EP | disclosed |
| US-20190328853-A1 | COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF HOOF AND CLAW DISEASES | POLYAKOV IGOR (DE) | 2019-10-31 | — | — | US | disclosed |
| EP-2635261-B1 | COMPOSITIONS AND METHODS FOR NANOPOLYMER-BASED NUCLEIC ACID DELIVERY | MARINE POLYMER TECH INC (US) | 2019-10-23 | — | — | EP | disclosed |
| US-5280113-A | Reacting oligosaccharide with ammonium bicarbonate; then a peptide | MONSANTO COMPANY (US) | 1994-01-18 | — | — | US | disclosed |
| US-5212298-A | Method for producing synthetic N-linked glycoconjugates | MONSANTO COMPANY (US) | 1993-05-18 | — | — | US | disclosed |
| EP-0538230-A1 | Method for producing synthetic N-linked glycoconjugates | OXFORD GLYCOSYSTEMS LTD. (GB) | 1993-04-21 | — | — | EP | disclosed |
| EP-0413675-A2 | Method for producing synthetic N-linked glycoconjugates | OXFORD GLYCOSYSTEMS LTD. (GB) | 1991-02-20 | — | — | EP | disclosed |
| EP-0299007-A4 | PREPARATION OF 1-AMINO-1-DEOXYOLIGOSACCHARIDES AND DERIVATIVES THEREOF. | GENZYME CORP (US) | 1990-03-08 | — | — | EP | disclosed |
| EP-0299007-A1 | PREPARATION OF 1-AMINO-1-DEOXYOLIGOSACCHARIDES AND DERIVATIVES THEREOF | GENZYME CORPORATION (US) | 1989-01-18 | — | — | EP | disclosed |
| WO-1988004323-A1 | PREPARATION OF 1-AMINO-1-DEOXYOLIGOSACCHARIDES AND DERIVATIVES THEREOF | GENZYME CORPORATION (US) | 1988-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190328853-A1 | COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF HOOF AND CLAW DISEASES | OAT, KRT18, TYR | USP2 3806/4885SLCO1B1 4109/4885LMNA 3212/4885 |
| US-11534483-B2 | Compositions for the treatment and prevention of hoof and claw diseases | OAT, KRT18, TYR | USP2 3806/4885SLCO1B1 4109/4885LMNA 3212/4885 |
| US-11173193-B2 | Immunobiological products | EPX, ICOS, LCT | USP2 3363/4885SLCO1B1 2637/4885LMNA 3954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.